Improved growth velocity of a patient with Noonan‐like syndrome with loose anagen hair (NS/LAH) without growth hormone deficiency by low‐dose growth hormone therapy
暂无分享,去创建一个
T. Morio | H. Ohashi | Y. Aoki | K. Kashimada | K. Takasawa | M. Nishioka | Masayuki Shimohira | S. Takishima | Chikako Morioka
[1] M. Tartaglia,et al. GH Therapy and first final height data in Noonan‐like syndrome with loose anagen hair (Mazzanti syndrome) , 2013, American journal of medical genetics. Part A.
[2] A. Pereira,et al. Growth standards of patients with Noonan and Noonan‐like syndromes with mutations in the RAS/MAPK pathway , 2012, American journal of medical genetics. Part A.
[3] C. Pignata,et al. Clinical Heterogeneity in two patients with Noonan-like Syndrome associated with the same SHOC2 mutation , 2012, Italian Journal of Pediatrics.
[4] C. Pignata,et al. Noonan‐like syndrome with loose anagen hair associated with growth hormone insensitivity and atypical neurological manifestations , 2012, American journal of medical genetics. Part A.
[5] B. Neel,et al. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature , 2012, Proceedings of the National Academy of Sciences.
[6] B. Gelb,et al. Noonan syndrome and clinically related disorders. , 2011, Best practice & research. Clinical endocrinology & metabolism.
[7] C. Mammucari,et al. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models , 2011, Skeletal Muscle.
[8] B. Gelb,et al. Disorders of dysregulated signal traffic through the RAS‐MAPK pathway: phenotypic spectrum and molecular mechanisms , 2010, Annals of the New York Academy of Sciences.
[9] J. Dahlgren. GH Therapy in Noonan Syndrome: Review of Final Height Data , 2009, Hormone Research in Paediatrics.
[10] Ravi Iyengar,et al. Mutation in SHOC2 promotes aberrant protein N-myristoylation and underlies Noonan-like syndrome with loose anagen hair , 2009, Nature Genetics.
[11] B. Bakker,et al. Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone. , 2009, The Journal of clinical endocrinology and metabolism.
[12] K. Rauen,et al. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. , 2009, Current opinion in genetics & development.
[13] Y. Matsubara,et al. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders , 2008, Human mutation.
[14] N. Wittekindt,et al. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. , 2005, The Journal of clinical endocrinology and metabolism.
[15] B. Mendonca,et al. PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome. , 2005, The Journal of clinical endocrinology and metabolism.
[16] L. Mazzanti,et al. Noonan‐like syndrome with loose anagen hair: A new syndrome? , 2003, American journal of medical genetics. Part A.
[17] M. Ranke,et al. Improvement of diagnostic criteria in growth hormone insensitivity syndrome: solutions and pitfalls , 1994, Acta paediatrica (Oslo, Norway : 1992). Supplement.
[18] R. B. Jensen,et al. [Growth hormone deficiency in children]. , 2015, Ugeskrift for laeger.
[19] F. Baldinotti,et al. IGF-I generation test in prepubertal children with Noonan syndrome due to mutations in the PTPN11 gene , 2013, Hormones.
[20] Ravi Iyengar,et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair , 2009 .
[21] G D'Hont,et al. [The Noonan syndrome]. , 1982, Acta oto-rhino-laryngologica Belgica.